Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-06-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于2022年度向特定对象发行股票摊薄即期回报的影响及其填补回报措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific issuance of shares to particular investors by the company 贝达药业股份有限公司 in 2022. It discusses the impact of this issuance on immediate earnings dilution, financial metrics such as earnings per share and return on equity, and the company's measures to mitigate these effects. It includes detailed financial assumptions, risk warnings, and commitments from controlling shareholders and management to uphold these measures. The content focuses on capital raising activities and the related financial impact analysis rather than presenting a full financial report or earnings release. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a simple announcement of a report publication but a substantive disclosure about a capital raising event and its financial implications. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5792 characters) and detailed financial impact analysis support this classification with high confidence.
2022-06-13 Chinese
前次募集资金使用情况鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Verification Report on the Use of Previous Fundraising Proceeds". It includes detailed financial data about the use of funds raised from previous stock issuances, including amounts raised, usage, investment projects, and verification by a registered accounting firm. The document references compliance with regulations from the China Securities Regulatory Commission regarding fundraising proceeds usage reports. It is a specialized report verifying the use of capital raised in prior financing rounds, with detailed tables and auditor's verification. This fits the category of a Capital/Financing Update (CAP), as it provides an update on the use of capital raised by the company. It is not a full annual or interim report, nor an audit report alone, but a specific report on fundraising proceeds usage. The document length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-06-13 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by the company 贝达药业股份有限公司, including specifics on amounts raised, usage, investment projects, changes in project allocations, and economic benefits realized. It references regulatory requirements from the China Securities Regulatory Commission and includes detailed financial figures and project status updates as of March 31, 2022. The content focuses on the actual use of funds raised in prior stock issuances, investment project changes, and compliance with regulatory reporting on fundraising. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document is not a full annual or interim report, nor is it an announcement or certification. It is a substantive report on fundraising usage and related financial details, fitting the CAP category.
2022-06-13 Chinese
关于向特定对象发行股票预案披露的提示性公告
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement (478 characters) regarding the company's plan to issue shares to specific investors. It mentions the approval of the issuance plan by the board and that the detailed plan has been disclosed on a regulatory website. It explicitly states that this announcement is a notice about the issuance plan and does not represent approval or completion of the issuance. There is no detailed financial data or full report included, only a notification about the share issuance plan. According to the classification rules, announcements about share issuance or capital changes fall under the category 'Share Issue/Capital Change' (SHA). The document is not a full report but an announcement, so it fits SHA rather than a full financial report or other categories.
2022-06-13 Chinese
关于2022年度向特定对象发行股票构成关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a specific transaction: the issuance of shares to a particular related party (the company's actual controller). It details the transaction overview, approval procedures, related party information, and the impact on the company. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about a capital raising event involving issuance of shares to a related party, which fits the category of Capital/Financing Update (CAP). The document length is about 2314 characters, which is typical for an announcement rather than a full report. Therefore, the correct classification is CAP.
2022-06-13 Chinese
关于最近五年不存在被证券监管部门和交易所处罚或采取监管措施及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (贝达药业股份有限公司) stating that in the past five years it has not been subject to any penalties or regulatory measures by securities regulatory authorities or exchanges. It includes a statement ensuring the truthfulness and completeness of the disclosure and references a board meeting date. The document length is only 500 characters, indicating it is a brief announcement rather than a detailed report. There is no financial data, no detailed audit or management discussion, and no presentation or voting results. It is a regulatory compliance announcement related to regulatory status and internal controls, which fits best under Regulatory Filings (RNS).
2022-06-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.